Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS0953/HM06 in Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250Phase 2Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Mar 2030
- Countries
- 4
01
Overview
A Phase 2 trial of vepafestinib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Taiho Pharmaceutical Co., Ltd.. Started Dec 2020; status: recruiting.
02
Drugs
vepafestinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04683250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683250.